Innovative Bispecific Antibodies TALVEY and TECVAYLI Show Promise for Treating Aggressive Multiple Myeloma New clinical results from Johnson & Johnson reveal the investigational combination of bispecific antibodies TALVEY and TECVAYLI demonstrates a high response rate in aggressive multiple myeloma patients.

Innovative Bispecific Antibodies TALVEY and TECVAYLI Show Promise for Treating Aggressive Multiple Myeloma #United_States #Johnson_&_Johnson #New_Brunswick #TALVEY #TECVAYLI